Given that IGFBP7 is upregulated in human pancreatic islets in type 2 diabetes, and that reversing this improves insulin secretion, IGFBP7 is emerging as a possible multi-tissue drug target in diabetes and other metabolic disorders. Here, INS is linked to metabolic disease.